Trial
NCT05312697
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ultragenyx Pharmaceutical Inc
Collaborators
Mereo BioPharma
Condition
Osteogenesis Imperfecta
Intervention
Setrusumab
Why stopped
Sponsor decision not related to safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-23